^
Association details:
Evidence:
Evidence Level:
Sensitive: B - Late Trials
Title:

Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451

Published date:
03/08/2021
Excerpt:
CheckMate 451, a double-blind phase III trial, evaluated nivolumab plus ipilimumab and nivolumab monotherapy as maintenance therapy following first-line chemotherapy for ED-SCLC....In the TMB-evaluable population, OS was improved with combination therapy versus placebo in patients with TMB ≥13 mut/Mb (HR, 0.61; 95% CI, 0.39 to 0.94; Fig 3A) but not in those with TMB<13 mut/Mb (HR, 1.04; 95% CI, 0.79 to 1.37; Fig 3B).
DOI:
10.1200/JCO.20.02212
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer

Excerpt:
...Only patients with high Tumor Mutation Burden are eligible....
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Tumor Mutation Burden and Efficacy of Nivolumab Monotherapy and in Combination With Ipilimumab in Small Cell Lung Cancer

Published date:
05/14/2018
Excerpt:
Efficacy of nivolumab ± ipilimumab was enhanced in patients with high tumor mutational burden. Nivolumab plus ipilimumab appeared to provide a greater clinical benefit than nivolumab monotherapy in the high tumor mutational burden tertile.
DOI:
10.1016/j.ccell.2018.04.001
Trial ID: